Rivaroxaban for Patients with Intermittent Claudication

BackgroundThe combination of rivaroxaban plus aspirin compared with aspirin alone reduces the risk of major adverse cardiovascular and limb events for high-risk patients with peripheral artery disease. It is unknown whether rivaroxaban plus aspirin improves intermittent claudication for adults with lower-risk peripheral arterial disease.MethodsIn this randomized, open-label, multicenter, 24-week clinical trial, we randomly assigned patients with peripheral artery disease and intermittent claudication to receive either 2.5 mg of rivaroxaban twice daily plus 100 mg of aspirin once daily or 100 mg of aspirin once daily. The primary outcome was a 24-week change in total walking distance, measured by the 6-minute walking test. The primary safety outcome was the incidence of major bleeding or clinically relevant nonmajor bleeding.ResultsEighty-eight patients were randomly assigned to either rivaroxaban plus aspirin (n=46) or aspirin alone (n=42). The mean age was 67 years, and 54% were female. The total walking distance measured by 6-minute walk test improved by 89 +/- 18 m (mean +/- standard error) in the rivaroxaban-plus-aspirin group versus 21 +/- 16 m in the aspirin-alone group. This corresponded to an absolute difference of 68 +/- 24 m (95% confidence interval [CI], 19 to 116 m; P=0.007) and a relative improvement over the aspirin-alone group of 327% (95% CI, 94 to 560%). No major bleeding events were observed in either group.ConclusionsIn patients with peripheral artery disease and intermittent claudication, 2.5 mg of rivaroxaban twice daily plus 100 mg of aspirin daily improved the total walking distance by a 6-minute walking test compared with 100 mg of aspirin daily alone. (Funded by Bayer S.A.; Clinicaltrials.gov number, NCT04853719.) In a randomized trial of 88 patients with peripheral artery disease and intermittent claudication who were followed for 24 weeks, rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily improved the total walking distance by a 6-minute walking test compared with aspirin 100 mg daily alone. Specifically, the absolute difference was 68 m farther for adults who received rivaroxaban plus aspirin.